John K. Clarke — Founder & Director at Alnylam Pharmaceuticals

Mr. John K. Clarke co-founded Cardinal Partners in 1997 and has been its Managing General Partner since October 1997. He spent two decades in venture capital industry, which he entered in 1982. Mr. Clarke is a part of the founding team at Vividion Therapeutics, Inc. Mr. Clarke served as General Partner at DSV. During his tenure there, he led its health care and life sciences efforts and co-founded and served as an Interim Chief Executive Officer of a number of companies including Alkermes, Arris Pharmaceuticals, the DNX Corporation and Cubist Pharmaceuticals. As a Managing Partner at DSV in latter years, Mr. Clarke led its evolution into Cardinal Partners. Mr. Clarke also worked at the General Electric Company in various sales and marketing positions. He served as the President and Chairman of Greater Philadelphia Venture Group. He has been the Chairman of aTyr Pharma Inc. since September 2005. He co-founded Alnylam Pharmaceuticals, Inc. and served as its Chairman since June 2002 until December 2015. He has been a Director of Alnylam Pharmaceuticals, Inc. since 2002. He served as a Director of Verastem Inc. since November 2010. He serves as a Director of Molecular Mining, Rib-X Pharmaceuticals, aTyr Pharma Inc., and VISICU, Inc. He served as a Director of TechRx and Momenta Pharmaceuticals, Inc until December 31, 2015. He served as a Director of Sirtris Pharmaceuticals, Inc. since 2004. He serves as a Trustee of Chamber Symphony of Princeton, Jackson Laboratory and Hands Together. He was on the National Venture Capital Association's Board of Directors. Mr. Clarke was a Founding Director of the Greater Philadelphia Venture Group. He served as a Director of the Greater Philadelphia Chamber of Commerce and the Board of the Philadelphia Industrial Development Corporation Penn Venture Group. Mr. Clarke has served as a Member of the University of Pennsylvania Advisory Panel on Technology Transfer. He received an A.B. in Economics and Biology from the Harvard University and an M.B.A. from the Wharton School at the University of Pennsylvania.